NasdaqGS:XERS

Stock Analysis Report

Executive Summary

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations.

Rewards

Trading at 96.6% below its fair value

Revenue is forecast to grow 66.56% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

Does not have meaningful revenue ($2M)



Snowflake Analysis

Adequate balance sheet and slightly overvalued.

Share Price & News

How has Xeris Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XERS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.8%

XERS

1.7%

US Pharmaceuticals

0.7%

US Market


1 Year Return

-56.1%

XERS

0.4%

US Pharmaceuticals

18.2%

US Market

Return vs Industry: XERS underperformed the US Pharmaceuticals industry which returned 0.4% over the past year.

Return vs Market: XERS underperformed the US Market which returned 18.2% over the past year.


Shareholder returns

XERSIndustryMarket
7 Day0.8%1.7%0.7%
30 Day10.6%4.4%1.5%
90 Day-13.2%7.1%5.0%
1 Year-56.1%-56.1%3.0%0.4%20.8%18.2%
3 Yearn/a30.3%20.9%45.2%35.8%
5 Yearn/a27.2%13.8%71.6%52.7%

Price Volatility Vs. Market

How volatile is Xeris Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Xeris Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: XERS ($8.87) is trading below our estimate of fair value ($260.07)

Significantly Below Fair Value: XERS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: XERS is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: XERS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XERS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XERS is overvalued based on its PB Ratio (5.5x) compared to the US Pharmaceuticals industry average (3x).


Next Steps

Future Growth

How is Xeris Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

51.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XERS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XERS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XERS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XERS's revenue (66.6% per year) is forecast to grow faster than the US market (7.4% per year).

High Growth Revenue: XERS's revenue (66.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XERS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Xeris Pharmaceuticals performed over the past 5 years?

-131.4%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: XERS is currently unprofitable.

Growing Profit Margin: XERS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if XERS's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare XERS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XERS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.3%).


Return on Equity

High ROE: XERS has a negative Return on Equity (-258.65%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Xeris Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: XERS's short term assets ($106.0M) exceed its short term liabilities ($17.8M).

Long Term Liabilities: XERS's short term assets ($106.0M) exceed its long term liabilities ($66.7M).


Debt to Equity History and Analysis

Debt Level: XERS's debt to equity ratio (133.1%) is considered high.

Reducing Debt: Insufficient data to determine if XERS's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: XERS has a low level of unsold assets or inventory.

Debt Coverage by Assets: XERS's debt is covered by short term assets (assets are 1.8x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XERS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: XERS has sufficient cash runway for 1.303238 years if free cash flow continues to reduce at historical rates of -58.3% each year.


Next Steps

Dividend

What is Xeris Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.7%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate XERS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate XERS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XERS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XERS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XERS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Xeris Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Paul Edick (63yo)

2.9yrs

Tenure

US$1,314,251

Compensation

Mr. Paul R. Edick has been the Chief Executive Officer, President and Director of Xeris Pharmaceuticals, Inc. since January 10, 2017 and has been its Chairman since June 2018. He was Chairman of the Board  ...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD1.31M) is about average for companies of similar size in the US market ($USD1.12M).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.


Management Age and Tenure

2.3yrs

Average Tenure

55.5yo

Average Age

Experienced Management: XERS's management team is considered experienced (2.3 years average tenure).


Board Age and Tenure

1.7yrs

Average Tenure

63yo

Average Age

Experienced Board: XERS's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: XERS insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$153,28327 Nov 19
Paul Edick
EntityIndividual
Role
Chief Executive Officer
President
Shares17,935
Max PriceUS$8.55
BuyUS$273,58512 Mar 19
Paul Edick
EntityIndividual
Role
Chief Executive Officer
President
Shares30,000
Max PriceUS$9.12
BuyUS$10,00025 Feb 19
Kenneth Johnson
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Clinical Development
Shares1,000
Max PriceUS$10.00
BuyUS$50,00023 Feb 19
Barry Deutsch
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares5,000
Max PriceUS$10.00
BuyUS$25,00022 Feb 19
Beth Hecht
EntityIndividual
Role
Chief Legal Officer
Senior VP
Shares2,500
Max PriceUS$10.00
BuyUS$5,880,00021 Feb 19
Redmile Group, LLC
EntityCompany
Shares588,000
Max PriceUS$10.00
SellUS$109,25112 Feb 19
Deerfield Management Company, L.P.
EntityCompany
Shares7,241
Max PriceUS$15.11
SellUS$222,44308 Feb 19
Deerfield Management Company, L.P.
EntityCompany
Shares14,807
Max PriceUS$15.07
SellUS$106,44830 Jan 19
Deerfield Management Company, L.P.
EntityCompany
Shares7,038
Max PriceUS$15.14
SellUS$1,766,19325 Jan 19
Deerfield Management Company, L.P.
EntityCompany
Shares114,444
Max PriceUS$16.35

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 234.6%.


Management Team

  • Beth Hecht (55yo)

    Senior VP

    • Tenure: 0yrs
  • Paul Edick (63yo)

    President

    • Tenure: 2.9yrs
    • Compensation: US$1.31m
  • Barry Deutsch (54yo)

    Chief Financial Officer

    • Tenure: 1.7yrs
    • Compensation: US$948.18k
  • Allison Wey

    Senior Vice President of Investor Relations & Corporate Communications

    • Tenure: 1.4yrs
  • Ken Johnson (56yo)

    Senior Vice President of Clinical Development

    • Tenure: 0yrs
  • Steve Prestrelski (55yo)

    Co-Founder & Chief Scientific Officer

    • Tenure: 0yrs
  • John Shannon (57yo)

    Executive VP & COO

    • Tenure: 2.8yrs
    • Compensation: US$918.49k
  • Kevin McCulloch

    Senior Vice President of Global Operations & Business Development

    • Tenure: 0yrs

Board Members

  • John Brooks (68yo)

    Scientific Advisory Board Member

    • Tenure: 0yrs
  • Orville Kolterman (71yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Jeff Sherman (64yo)

    Independent Non-Executive Board Member

    • Tenure: 1.7yrs
    • Compensation: US$164.76k
  • John Schmid (56yo)

    Independent Non-Executive Board Member

    • Tenure: 2.3yrs
    • Compensation: US$224.75k
  • Paul Edick (63yo)

    President

    • Tenure: 2.9yrs
    • Compensation: US$1.31m
  • Ken Ward

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Marla Persky (63yo)

    Independent Non-Executive Board Member

    • Tenure: 1.7yrs
    • Compensation: US$169.26k
  • Morey Haymond

    Scientific Advisory Board Member

    • Tenure: 0yrs
  • Barbar-Jean Bormann-Kennedy (60yo)

    Independent Non-Executive Board Member

    • Tenure: 1.7yrs
    • Compensation: US$172.26k
  • Dawn Halkuff (48yo)

    Independent Non-Executive Board Member

    • Tenure: 1.7yrs
    • Compensation: US$167.76k

Company Information

Xeris Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Xeris Pharmaceuticals, Inc.
  • Ticker: XERS
  • Exchange: NasdaqGS
  • Founded: 2005
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$239.446m
  • Shares outstanding: 27.00m
  • Website: https://www.xerispharma.com

Number of Employees


Location

  • Xeris Pharmaceuticals, Inc.
  • 180 North LaSalle Street
  • Suite 1810
  • Chicago
  • Illinois
  • 60601
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XERSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 2018
2B3DB (Deutsche Boerse AG)YesCommon StockDEEURJun 2018

Biography

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation techno ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/10 00:51
End of Day Share Price2019/12/09 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.